The United States Axial Spondyloarthritis market which currently has a market size of ~USD 1.3 Bn. is projected to grow at a CAGR of ~9.5% in the next five years as per the findings of Ken Research.
Story Outline
- Rising cases of Axial Spondyloarthritis pose as a demand for the correct diagnosis and treatment of AxSpA which helps in the growth of US AxSpA market.
- Increasing US health expenditure allows hospitals, research institutes and pharmaceutical company to research, diagnose, and treat AxSpA thereby accelerating the US AxSpA market.
- Technological advancements in diagnosing AxSpA such as MRI, CT scan, and ultrasound can provide early and correct diagnosis which pumps the US AxSpA market.
- Availability of various treatment options also help in the effective and efficient treatment of AxSpA which contributes in the growth of US AxSpA market.
A fast growing industry, rising cases of Axial Spondyloarthritis, increasing health expenditure, and technological advancements along with the availability of many treatment methods are the various reasons that are contributing to the growth of US Axial Spondyloarthritis market. This market is projected to grow at a CAGR of ~9.5% in between 2022-2028.
Click to read more about US Axial Spondyloarthritis market
- Rising cases of Axial Spondyloarthritis: accelerating the US AxSpA market
Click to Download a Free Sample Report
Axial Spondyloarthritis is group of inflammatory disorders which have the traits of autoimmune diseases. It is primarily of two types, i.e., Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis. The prevalence of Axial Spondyloarthritis is very high in the United States. It ranges in between 0.9% to 1.4%. Moreover, in the United States, more than 3 million people suffer from Axial Spondyloarthritis.
It’s one of the most common subtype, i.e., Ankylosing Spondylitis almost affects 1% of the US population. Its second type, i.e., Non-Radiographic Axial Spondyloarthritis affects about 0.5% of the US population. Speaking of its incidence rate, it was 0.39 in 2007 and rose from 0.39 to 0.57 in 2017. It is clear that the cases of Axial Spondyloarthritis is only rising in the United States and we will be seeing more cases of it in the near future.
Axial Spondyloarthritis is primarily caused by the presence of HLA-B27 gene and a high number of people in the US have this gene which increases their chances of developing Axial Spondyloarthritis in the future.
Overall, the prevalence of this gene is 3.5% in overall US population. Almost 7.5% of the Hispanic-White people have this gene. This gene is present in about 4.5% of the American-Mexican people. Lastly, 1% of Black-Non-Hispanic people have this gene. With such high prevalence of Axial Spondyloarthritis, there becomes a greater need to correctly diagnose the patients and furthermore, correctly treat them which ultimately helps in the growth of US Axial Spondyloarthritis market.
- Rising health expenditure: contributing in the growth of US AxSpA market
Click to Download a Free Sample Report
The national health expenditure in the US has been constantly rising in the United States. The rising health expenditure helps hospitals, research institutes and pharmaceutical companies in correctly diagnosing and treating AxSpA. It also helps pharmaceutical companies in developing more medicines and therapies to help in the effective and efficient treatment of AxSpA.
In 2017, the US government made a health expenditure of ~USD 3.4 Tn. In 2018, ~USD 3.6 Tn. worth of expenditure was made in the healthcare sector. In 2019, this amount rose to ~USD 3.7 Tn. In 2020, a healthcare budget worth of ~USD 4.1 Tn. was allocated. Lastly in 2021, the US government made a healthcare expenditure of ~USD 4.2 Tn.
As it is evident, that the healthcare expenditure in the United States have only been rising and it is projected to rise further in the upcoming years. The rising expenditure would allow hospitals, diagnostic laboratories, pharmaceutical companies and research institutes to research, diagnose, and treat Axial Spondyloarthritis along with develop first line medicines and alternative therapies to effectively treat Axial Spondyloarthritis.
- Technological advancements: a boon for the US Axial Spondyloarthritis market
Visit this Link: – Request for custom report
Various technologies are used in the effective and correct diagnosis of Axial Spondyloarthritis. Some of the most common technologies used in the diagnosis of Axial Spondyloarthritis include Magnetic Resonance Imaging (MRI), Ultrasound, Gene Testing, and Computerized Tomography (CT) scan.
A Magnetic Resonance Imaging (MRI) is the most common method of diagnosing Axial Spondyloarthritis. This technology works by taking the cross-sectional images of your body parts with the help of radio waves and magnetic field.
It has a success rate of almost 80 to 97%. It helps in AxSpA diagnosis as it has the ability to detect early changes happening in the Sacroiliitis.
Ultrasound is another technology that is primarily used to diagnose AxSpA. It works by sending the body sound signals or ways as the internal body is examined. It is primarily used to take a look at the inflammation of Sacroiliac Joints to diagnose Ankylosing Spondylitis. The success rate of ultrasound ranges from 90% to 97%.
A Computerized Tomography (CT) scan is another technology that is used to diagnose AxSpA. It provides valuable information in regard for osteoporosis, ankyloses, erosion etc. which extremely helps in making the correct diagnosis of AxSpA. This scan has a success rate of almost 85%.
Thus, technology is indeed a boom for the US AxSpA market as the task of correctly diagnosing ankylosing spondylitis and non-radiographic Axial Spondyloarthritis has become greatly easier. With these technological advancements, early diagnosis is made which accelerates the US AxSpA market.
- Availability of many treatment methods:
Request free 30 minutes analyst call
There are many treatment options when it comes to Axial Spondyloarthritis. NSAIDs, Biologics, Analgesics, and Glucocorticoids are primarily used in the effective treatment of Axial Spondyloarthritis.
NSAIDs is an initialism for Non-Steroidal Anti-inflammatory drugs. These drugs are the first line treatment of AxSpA which causes high pain and inflammation. These drugs reduce the pain and inflammation. The most common NSAIDs used in the treatment of AxSpA include Ibuprofen, Naproxen, and Diclofenac.
Biologics are another set of medications that are primarily used to treat Axial Spondyloarthritis. These medicines are generally given to such patients who do not respond to NSAIDs. Common biologics used to treat AxSpA include Adalimumab, Etanercept, Infliximab, Crtolizumab pegol, etc.
Sulfasalazine is a type of anti-rheumatic drugs which is primarily given to patients who complain of pain in other joints than the spine and pelvis ones. Moreover, this drug also has is known to make your back less painful and stiff.
Glucocorticoids can be best described as a type of steroids which are generally given for pain relief. These are anti-inflammatory and generally come in the form of injections.
Thus, there are many treatment options available for the treatment of Axial Spondyloarthritis. As the treatment options are widely present, more and more patients widely benefit from them which ultimately accelerates the US AxSpA market.
Conclusion
Axial Spondyloarthritis is an inflammatory health condition which is of two types, Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. The US AxSpA market is associated with the diagnosis and treatment of AxSpA.
There are various factors responsible for the growth of this market which include rising cases of Axial Spondyloarthritis, increasing health expenditure, and technological advancements along with the availability of many treatment methods. As per Ken Research, this market is projected to grow at a CAGR of ~9.5% in the next five years.
